Q3 2024 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2024-11-14 · accession 0001214659-24-019064
$1.18B
Reported value
36
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY, INC. | $138.5M | 11.7% | 3,670,206 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS, INC | $95.2M | 8.07% | 2,650,150 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $75.2M | 6.37% | 6,964,375 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA | $69.8M | 5.91% | 6,056,596 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS, INC. | $56.4M | 4.78% | 2,112,984 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $55.2M | 4.67% | 3,033,560 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC. | $52.4M | 4.44% | 12,362,205 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS, INC. | $51.1M | 4.33% | 879,344 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $48.8M | 4.14% | 2,427,138 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $46.8M | 3.96% | 1,989,103 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $46.7M | 3.95% | 1,063,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX, INC. | $46.3M | 3.92% | 5,319,148 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $46.2M | 3.92% | 2,890,816 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $38.0M | 3.22% | 1,477,593 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $32.7M | 2.77% | 2,415,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS, INC. | $30.4M | 2.58% | 2,761,861 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS, INC. | $29.9M | 2.53% | 2,470,265 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $27.8M | 2.36% | 1,423,642 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTIVS, INC. | $27.8M | 2.35% | 550,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $24.3M | 2.06% | 3,858,000 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $23.9M | 2.03% | 486,957 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $18.7M | 1.59% | 5,250,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $16.9M | 1.43% | 650,000 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $15.0M | 1.27% | 4,643,812 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES, INC. | $14.1M | 1.19% | 2,008,339 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $9.3M | 0.79% | 584,955 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $8.1M | 0.68% | 2,676,580 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS, INC. | $7.6M | 0.65% | 231,820 | Common | SOLE |
| 30233G209 | EYPT | EyePoint Pharmaceuticals, Inc. | $7.4M | 0.62% | 922,335 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $5.2M | 0.44% | 4,000,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $4.7M | 0.40% | 2,240,809 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $4.6M | 0.39% | 483,000 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $2.6M | 0.22% | 1,008,158 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics, Inc. | $1.7M | 0.14% | 1,555,118 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES, INC | $689,305 | 0.06% | 316,195 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO, INC | $409,672 | 0.03% | 86,795 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.